From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

S-adenosylmethionine or SAME-e is an amino acid creates of methionine that is synthesized in the body that acts as the body's main methyl donor in many different metabolic reactions.[1]

S-adenosylmethionine is available as a nutritional supplement and is also known as:

  • ADE-SD4
  • Ademetionine, *Adenosylmethionine
  • S-Adenosyl Methionine, S-Adenosyl-L-Methionine or S-Adenosylmethionine,
  • S-Adenosylmethionine Butanedisulfonate
  • S-Adenosylmethionine Tosylate, S-Adenosylmethionine Tosylate Disulfate,
  • SAMe or SAM-e,
  • Sammy or Samyr,

and abbreviated as:

  • AdoMet, SAM-e or SAMe,[2]

S-adenosylmethionine may become depleted with B-vitamin deficiency, chronic inflammation, and has been observed to decrease with age.[citation needed]

Theory[edit | edit source]

Low levels of SAMe have been found in people with liver disease and depression. It may also have a role in reducing pain or help reduce symptoms of osteoarthritis or other illnesses.[1][3]

SAMe may help people with ME/CFS by restoring methyl donor levels, allowing methylation reactions to continue at a normal rate. If there is a deficiency of methyl donors in the central nervous system, SAMe supplementation might be expected to improve some brain function, or improve mood. Among many other synthetic reactions, SAMe aids in the synthesis of the neurotransmitters norepinephrine, dopamine, and serotonin.

Evidence[edit | edit source]

A small number of studies have been conducted in fibromyalgia patients which showed some positive effects when taking SAMe.[4][5][6][7] The main positive effect has been described as a reduction in pain levels.[7] However, Volkmann et al (2009) found no significant effect in a ten day trial of fibromyalgia patients.[8]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "S-Adenosyl-L-Methionine (SAMe): In Depth". National Center for Complimentary and Integrative Health. January 2017. Retrieved February 26, 2021.
  2. "SAMe Uses, Benefits & Dosage - Herbal Database". Retrieved October 15, 2019.
  3. "SAM-e (Ademetionine, SAMe)". WebMD. Retrieved February 27, 2021.
  4. Di Benedetto, P.; Iona, L.G.; Zidarich, V. (February 1, 1993). "Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia". Current Therapeutic Research. 53 (2): 222–229. doi:10.1016/S0011-393X(05)80250-4. ISSN 0011-393X.
  5. Jacobsen, S.; Danneskiold-Samsøe, B.; Andersen, R.B. (1991). "Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation". Scandinavian Journal of Rheumatology. 20 (4): 294–302. doi:10.3109/03009749109096803. ISSN 0300-9742. PMID 1925418.
  6. Tavoni, A.; Vitali, C.; Bombardieri, S.; Pasero, G. (November 20, 1987). "Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study". The American Journal of Medicine. 83 (5A): 107–110. doi:10.1016/0002-9343(87)90862-x. ISSN 0002-9343. PMID 3318438.
  7. 7.0 7.1 Edwards, A.M.; Blackburn, L.; Christie, S.; Townsend, S.; David, J. (January 1, 2000). "Food Supplements in the Treatment of Primary Fibromyalgia: A Double-blind, Crossover Trial of Anthocyanidins and Placebo". Journal of Nutritional & Environmental Medicine. 10 (3): 189–199. doi:10.1080/13590840050134863. ISSN 1359-0847.
  8. Volkmann, H.; Norregaard, J.; Jacobsen, S.; Danneskiold-samsøe, B.; Knoke, G.; Nehrdich, D. (January 1, 1997). "Double-blind, Placebo-controlled Cross-over Study of Intravenous S-Adenosyl-L-Methionine in Patients with Fibromyalgia". Scandinavian Journal of Rheumatology. 26 (3): 206–211. doi:10.3109/03009749709065682. ISSN 0300-9742.